Onset age and severity of motor impairment are associated with reduction of myocardial 123I-MIBG uptake in Parkinson's disease

J Neurol Neurosurg Psychiatry. 2003 Apr;74(4):423-6. doi: 10.1136/jnnp.74.4.423.

Abstract

Objectives: To elucidate the factors associated with severity of cardiac sympathetic nerve involvement in idiopathic Parkinson's disease (PD).

Methods: (123)I-metaiodobenzylguanidine uptake was examined in 88 patients with PD. The ratio of the uptake in the heart (H) to that in the mediastinum (M) (the H/M ratio) was calculated and correlated with age at onset, age at examination, and disease severity and duration. Twenty five healthy people were also examined as a control.

Results: There was a mild but significant negative correlation between H/M ratio and age at onset (early, r = -0.33, p = 0.002; delayed, r = -0.34, p = 0.001) and between Hoehn and Yahr (H-Y) stage (early, r = -0.30, p = 0.006; delayed, r = -0.32, p = 0.003). There was no significant correlation between disease duration and H/M ratio. When patients with PD were classified into four subgroups on the basis of age at onset (> 62 or < 62 years) and disease severity (H-Y > III or H-Y < or = II), the median H/M ratio of the older and more severe group was significantly lower than that of the younger and less severe group (p = 0.005).

Conclusion: This study suggests that late onset, high severity PD is associated with myocardial sympathetic dysfunction.

MeSH terms

  • 3-Iodobenzylguanidine / pharmacokinetics*
  • Age Factors
  • Age of Onset*
  • Aged
  • Aged, 80 and over
  • Autonomic Nervous System Diseases / diagnostic imaging*
  • Autonomic Nervous System Diseases / etiology*
  • Female
  • Heart / diagnostic imaging
  • Heart Diseases / diagnostic imaging*
  • Heart Diseases / etiology*
  • Humans
  • Male
  • Mediastinum / diagnostic imaging
  • Middle Aged
  • Parkinson Disease / complications*
  • Parkinson Disease / diagnostic imaging*
  • Predictive Value of Tests
  • Radionuclide Imaging
  • Radiopharmaceuticals / pharmacokinetics*
  • Risk Factors
  • Severity of Illness Index*
  • Time Factors

Substances

  • Radiopharmaceuticals
  • 3-Iodobenzylguanidine